- Volume 16 Issue 16
DOI QR Code
IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation
- Malek-Hosseini, Zahra (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
- Taherinejad, Marziye (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
- Malekzadeh, Mahyar (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
- Ghaderi, Abbas (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
- Doroudchi, Mehrnoosh (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences)
- Published : 2015.11.04
Background: Inflammation plays a major role in the development and progression of gastric and other gastrointestinal tumors. The IL-17 family of cytokines has been under investigation as targets of immunotherapy. Materials and Methods: We investigated the levels of IL-17A inflammatory cytokine in the sera of 57 patients with gastric cancer (GC) and 90 healthy age/sex matched controls using ELISA methods. Results: In only 5 (8.8%) of the patients' sera was IL-17A detectable. No IL-17A was apparent in the sera of healthy controls. The maximum concentration of IL-17A in patients was 7.004 pg/ml. Vascular and lymphatic invasions were only seen in one of the 5 positive cases. Although all of them were in the age group >60 years, no correlation was seen between age and IL-17A level. These results are somewhat different from our findings for colorectal cancer (CRC) in the same population. Conclusions: It is possible that the inflammopathology of CRC and GC are rather different, at least in Fars, a southern province of Iran.
- Benchetrit F, Ciree A, Vives V, et al (2002). Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood, 99, 2114-21. https://doi.org/10.1182/blood.V99.6.2114
- Cancer incidence in five continents (2002). Volume VIII. IARC Sci Publ, 1-781.
- Caruso R, Pallone F, Monteleone G (2007). Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol, 13, 5547-51. https://doi.org/10.3748/wjg.v13.i42.5547
- Coupland VH, Lagergren J, Konfortion J, et al (2012). Ethnicity in relation to incidence of oesophageal and gastric cancer in England. Br J Cancer, 107, 1908-14. https://doi.org/10.1038/bjc.2012.465
- Doroudchi M, Pishe ZG, Malekzadeh M, et al (2013a). Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev, 14, 5225-30. https://doi.org/10.7314/APJCP.2013.14.9.5225
- Doroudchi M, Saidi M, Malekzadeh M, et al (2013b). Elevated IL-17A levels in early stages of bladder cancer regardless of smoking status. Future Oncol, 9, 295-304. https://doi.org/10.2217/fon.12.180
- Eshraghian A (2014). Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol, 20, 17618-25. https://doi.org/10.3748/wjg.v20.i46.17618
- Ghasemi-Kebria F, Ghaemi E, Azadfar S, et al (2013). Epidemiology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol, 14, 4.
- Hassanzade J, Molavi e vardanjan iH, Farahmand M, et al (2011). Incidence and mortality rate of common gastrointestinal cancers in south of iran, a population based study. Iran J Cancer Prev, 4, 7.
- He S, Fei M, Wu Y, et al (2011). Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci, 12, 7424-37. https://doi.org/10.3390/ijms12117424
- Jafarzadeh A, Mirzaee V, Ahmad-Beygi H, et al (2009). Association of the CagA status of Helicobacter pylori and serum levels of interleukin (IL)-17 and IL-23 in duodenal ulcer patients. J Dig Dis, 10, 107-12. https://doi.org/10.1111/j.1751-2980.2009.00371.x
- Jin W, Dong C (2013). IL-17 cytokines in immunity and inflammation. Emerging Microbes and Infections, 2, 1-5. https://doi.org/10.1038/emi.2013.1
- Kryczek I, Wei S, Szeliga W, et al (2009). Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood, 114, 357-9. https://doi.org/10.1182/blood-2008-09-177360
- Landskron G, De la Fuente M, Thuwajit P, et al (2014). Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014, 149185.
- Layke JC, Lopez PP (2004). Gastric cancer: diagnosis and treatment options. Am Fam Physician, 69, 1133-40.
- Liu C, Zhang Y, Zhan J, et al (2014a). Interleukin-23A is associated with tumor growth in Helicobacter-pylori-related human gastric cancer. Cancer Cell Int, 14, 104. https://doi.org/10.1186/s12935-014-0104-x
- Liu X, Jin H, Zhang G, et al (2014b). Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS One, 9, 106834. https://doi.org/10.1371/journal.pone.0106834
- Lv L, Pan K, Li XD, et al (2011). The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One, 6, 18219. https://doi.org/10.1371/journal.pone.0018219
- Ma C, Dong X (2011). Colorectal cancer-derived Foxp3(+) IL- 17(+) T cells suppress tumour-specific CD8+ T cells. Scand J Immunol, 74, 47-51. https://doi.org/10.1111/j.1365-3083.2011.02539.x
- Ma M, Jin GJ, Yun K, et al (2015). Correlation of IL-1F genetic polymorphisms with the risk of colorectal cancer among Chinese populations. Tumour Biol, 36, 807-14. https://doi.org/10.1007/s13277-014-2653-y
- Malekzadeh M, Dehaghani AS, Ghaderi A, et al (2013). IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. Cancer Biomark, 13, 417-25.
- Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009). Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med, 12, 576-83.
- Matveeva LV, Mosina LM (2013). The changes in serum concentrations of interleukin-17 in diseases gastroduodenal zone. Eksp Klin Gastroenterol, 8, 24-7.
- Mehrabani D, Hosseini SV, Rezaianzadeh A, et al (2013). Prevalence of stomach cancer in Shiraz, Southern Iran. J Res Med Sci, 18, 335-7.
- Meng XY, Zhou CH, Ma J, et al (2012). Expression of interleukin-17 and its clinical significance in gastric cancer patients. Med Oncol, 29, 3024-8. https://doi.org/10.1007/s12032-012-0273-1
- Murugaiyan G, Saha B (2009). Protumor vs antitumor functions of IL-17. J Immunol, 183, 4169-75. https://doi.org/10.4049/jimmunol.0901017
- Nemati K, Golmoghaddam H, Hosseini SV, et al (2015). Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression. Gene, 561, 88-94. https://doi.org/10.1016/j.gene.2015.02.014
- Niknam R, Seddigh M, Fattahi MR, et al (2014). Prevalence of Helicobacter pylori in Patients With Dyspepsia. Jundishapur J Microbiol, 7, 12676.
- Numasaki M, Fukushi J, Ono M, et al (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101, 2620-7. https://doi.org/10.1182/blood-2002-05-1461
- Oluwasola AO (2014). Genetic determinants and clinicopathological outcomes of Helicobacter pylori infection. Ann Ib Postgrad Med, 12, 22-30.
- Omrane I, Marrakchi R, Baroudi O, et al (2014). Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol, 35, 6627-32. https://doi.org/10.1007/s13277-014-1890-4
- Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Petanidis S, Anestakis D, Argyraki M, et al (2013). Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One, 8, 73616. https://doi.org/10.1371/journal.pone.0073616
- Ren Z, Li M, Liu R, et al (2014). Interleukin 17A rs3819024 A>G polymorphism is associated with an increased risk of gastric cardia adenocarcinoma in a Chinese population. Biomarkers, 19, 411-6. https://doi.org/10.3109/1354750X.2014.924158
- Rokkappanavar K Kumar SSR, Esaki M Shankar, E Ganapathy, Abdul S Ebrahim, Shukkur M Farooq (2013). Gastric Carcinoma- New Insights into Current Management 271-93, edited by Daniela Lazar, ISBN 978-953-51-0914-3, InTech, January 1, 2013
- Saito H, Yamada Y, Takaya S, et al (2015). Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer. Surg Today.
- Su X, Ye J, Hsueh EC, et al (2010). Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol, 184, 1630-41. https://doi.org/10.4049/jimmunol.0902813
- Tesmer LA, Lundy SK, Sarkar S, et al (2008). Th17 cells in human disease. Immunol Rev, 223, 87-113. https://doi.org/10.1111/j.1600-065X.2008.00628.x
- Toy D, Kugler D, Wolfson M, et al (2006). Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol, 177, 36-9. https://doi.org/10.4049/jimmunol.177.1.36
- Tsugane S, Sasazuki S (2007). Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer, 10, 75-83. https://doi.org/10.1007/s10120-007-0420-0
- Wang L, Yi T, Kortylewski M, et al (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med, 206, 1457-64. https://doi.org/10.1084/jem.20090207
- Wang N, Yang J, Lu J, et al (2014). IL-17 gene polymorphism is associated with susceptibility to gastric cancer. Tumour Biol, 35, 10025-30. https://doi.org/10.1007/s13277-014-2255-8
- Wu D, Wu P, Huang Q, et al (2013). Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol, 2013, 436307.
- Yan S, Li B, Bai ZZ, et al (2014). Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer. World J Gastroenterol, 20, 10486-94. https://doi.org/10.3748/wjg.v20.i30.10486
- Yu H, Sun S, Liu F, et al (2014). Meta-analysis of associations between interleukin-17 gene polymorphisms and risk of gastric cancer. Asian Pac J Cancer Prev, 15, 8709-13. https://doi.org/10.7314/APJCP.2014.15.20.8709
- Zhang JP, Yan J, Xu J, et al (2009). Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol, 5, 980-9.
- Interleukins 17 and 23 in patients with gastric neoplasms vol.6, pp.1, 2016, https://doi.org/10.1038/srep37451